While complete regression of kidney damage remains a challenging goal, accumulating evidence suggests that early intervention—particularly with individualized combinations of RAAS inhibitors, SGLT2i, GLP1-RAs, MRAs—can significantly slow progression and, in select cases, induce partial regression. This evidence concerns the gene GCG and Nephropathy.